[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349594-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349594-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","thirty-years-of-nci-thyroid-cancer-research-investment-19962025-a-longitudinal-portfolio-analysis-of-funding-trends-molecular-target-emphasis-and-thematic-evolution","Thirty years of NCI thyroid cancer research investment (1996–2025) - a longitudinal portfolio analysis of funding trends, molecular target emphasis and thematic evolution","","Research funding for thyroid cancer has shifted over three decades toward molecular classification, precision diagnostics, and targeted therapy, yet investment evolution has not been systematically quantified. A longitudinal portfolio analysis of NIH RePORTER records (1996–2025) identified NCI-administered thyroid-relevant projects, coded research stage, subtype, molecular targets, and modalities, and applied biomedical embeddings and BERTopic for thematic domains. Results quantify $343.8M (2025 dollars) cumulative funding and show increasing translational, molecularly informed, clinically oriented emphasis, with thematic movement toward diagnosis, risk stratification, signaling, and therapies for advanced disease.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/thirty-years-of-nci-thyroid-cancer-research-investment-19962025-a-longitudinal-portfolio-analysis-of-funding-trends-molecular-target-emphasis-and-thematic-evolution/349594/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/thirty-years-of-nci-thyroid-cancer-research-investment-19962025-a-longitudinal-portfolio-analysis-of-funding-trends-molecular-target-emphasis-and-thematic-evolution/349594.png","ImageObject",300,407,{"name":42,"@type":43},"hdkawk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What dataset and study period were used to analyze NCI thyroid cancer research investment?","Question",{"text":63,"@type":64},"The study analyzed National Institutes of Health (NIH) RePORTER records for fiscal years 1996–2025, focusing on NCI-administered projects with explicit thyroid cancer research relevance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study identify and code molecular targets and research themes?",{"text":68,"@type":64},"Rule-based dictionaries annotated research stage, disease subtype, molecular targets, and therapeutic or diagnostic modalities, and deduplicated project text was analyzed using MedCPT biomedical embeddings with BERTopic to identify higher-order thematic domains.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings about trends in funding and research focus?",{"text":72,"@type":64},"Annual research activity increased over time, peaking in 2015, and the portfolio shifted toward translational and mixed clinical–preclinical work. Topic modeling indicated a movement from broad thyroid cancer characterization toward diagnosis and risk stratification, molecular signaling, treatment-response biology, and therapeutics for aggressive or advanced disease.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349594,1790411951,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TYPE Original Research PUBLISHED 17 August 2026  \nDOI 10.3389/fonc.2026.1876183  \nOPEN ACCESS  \nEDITED BY  \nFutoshi Suizu,  \nKagawa Prefectural University of Health Sciences, Japan  \nREVIEWED BY  \nBakr Alhayek,  \nAdventHealth Graduate Medical Education, United States Nannan Lai,  \nShanxi Medical University, China  \n*CORRESPONDENCE  \nFei Le  \n [lefeincu@163.com](lefeincu@163.com)  \n†These authors have contributed equally to this work  \nRECEIVED 08 May 2026  \nREVISED 22 June 2026  \nACCEPTED 24 July 2026  \nPUBLISHED 17 August 2026  \nCITATION  \nJiang Y, Chen Y, Lai X and Le F (2026) Thirty years of NCI thyroid cancer research investment (1996–2025): a longitudinal portfolio analysis of funding trends, molecular target emphasis and thematic evolution.  \nFront. Oncol. 16:1876183 .  \ndoi: 10.3389/fonc.2026.1876183  \nCOPYRIGHT  \n© 2026 Jiang, Chen, Lai and Le. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThirty years of NCI thyroid cancer research investment (1996–2025): a longitudinal portfolio analysis of funding trends, molecular target emphasis and thematic evolution  \nYoufang Jiang 1†, Yaoyao Chen 1†, Xinrong Lai 2 and Fei Le 1* 1 Department of Head and Neck Surgery, Jiangxi Cancer Hospital, The Second Afﬁliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer, Nanchang, China, 2School of  \nClinical Medicine, Nanchang Medical College, Nanchang, China  \nBackground: Thyroid cancer research has shifted over the past three decades toward molecular classiﬁcation, precision diagnostics and targeted therapy. However, the evolution of public research investment in this ﬁeld has not been systematically characterized. This study analyzed National Cancer Institute (NCI) -administered thyroid cancer research funding from 1996 to 2025 .  \nMethods: We performed a longitudinal portfolio analysis of NIH RePORTER records from ﬁscal years 1996–2025 . NCI-administered projects with explicit thyroid cancer research relevance were identiﬁed through review of project titles, abstracts, public health relevance statements and project terms. The ﬁnal analytic cohort comprised 753 project-award years (AYs) . Rule-based dictionaries were used to annotate research stage, disease subtype, molecular target and therapeutic or diagnostic modality. Deduplicated project text was further analyzed using MedCPT biomedical embeddings and BERTopic to identify higher-order thematic domains.  \nResults: The cohort represented approximately USD 343 . 8 million in cumulative NCI funding in BRDPI-adjusted 2025 U. S. dollars. Annual research activity increased over time, peaking in 2015 with 53 active AYs and approximately USD 24. 8 million in BRDPI-adjusted 2025 U. S. dollars. Translational or mixed clinical– preclinical research accounted for the largest share of the portfolio (46.5%), and R01 awards were the dominant funding mechanism (48 . 5%) . Papillary thyroid carcinoma was the most frequently annotated subtype, followed by anaplastic, differentiated, follicular, poorly differentiated and medullary thyroid cancers. BRAF, RET, MAPK/MEK, PI3K/AKT/mTOR and RAS were the leading molecular targets. Topic modelling identiﬁed ﬁve higher-order thematic domains, suggesting a relative shift from broad thyroid cancer characterization toward diagnosis and risk stratiﬁcation, molecular signaling, treatment-response biology and therapeutics for aggressive or advanced disease.  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \nConclusions: NCI-administered thyroid cancer research funding expanded between 1996 and 2025 and became increasing","cbCailuVc3y6c4gr","https://ap.wps.com/l/cbCailuVc3y6c4gr","pdf",3039878,"English","# Introduction\n## Methods\n# Results\n# Conclusions","[{\"question\":\"What dataset and study period were used to analyze NCI thyroid cancer research investment?\",\"answer\":\"The study analyzed National Institutes of Health (NIH) RePORTER records for fiscal years 1996–2025, focusing on NCI-administered projects with explicit thyroid cancer research relevance.\"},{\"question\":\"How did the study identify and code molecular targets and research themes?\",\"answer\":\"Rule-based dictionaries annotated research stage, disease subtype, molecular targets, and therapeutic or diagnostic modalities, and deduplicated project text was analyzed using MedCPT biomedical embeddings with BERTopic to identify higher-order thematic domains.\"},{\"question\":\"What were the main findings about trends in funding and research focus?\",\"answer\":\"Annual research activity increased over time, peaking in 2015, and the portfolio shifted toward translational and mixed clinical–preclinical work. Topic modeling indicated a movement from broad thyroid cancer characterization toward diagnosis and risk stratification, molecular signaling, treatment-response biology, and therapeutics for aggressive or advanced disease.\"}]","Thirty years of NCI thyroid cancer research investment (1996–2025) - a longitudinal portfolio analysis of funding trends, molecular target emphasis and thematic evolution | PDF",1790084440,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5af93158942118f5417f9d235ac4721e.webp",983,1389,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/301cfa3fac611e670533ac974a5e6f5d.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7dfff0e62e4ac47d675814b17e18c083.webp",981,1386,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ba58c5dd5c687bf4fa1ebe192af655f.webp",980,1385]